TY - JOUR
T1 - The impact of artificial intelligence on retinal disease management
T2 - Vision Academy retinal expert consensus
AU - Danese, Carla
AU - Kale, Aditya U.
AU - Aslam, Tariq
AU - Lanzetta, Paolo
AU - Barratt, Jane
AU - Chou, Yu Bai
AU - Eldem, Bora
AU - Eter, Nicole
AU - Gale, Richard
AU - Korobelnik, Jean François
AU - Kozak, Igor
AU - Li, Xiaorong
AU - Li, Xiaoxin
AU - Loewenstein, Anat
AU - Ruamviboonsuk, Paisan
AU - Sakamoto, Taiji
AU - Ting, Daniel S.W.
AU - Van Wijngaarden, Peter
AU - Waldstein, Sebastian M.
AU - Wong, David
AU - Wu, Lihteh
AU - Zapata, Miguel A.
AU - Zarranz-Ventura, Javier
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Purpose of reviewThe aim of this review is to define the "state-of-the-art" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.Recent findingsMost of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.SummaryIt is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.
AB - Purpose of reviewThe aim of this review is to define the "state-of-the-art" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.Recent findingsMost of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.SummaryIt is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.
KW - artificial intelligence
KW - disease management
KW - retina
UR - http://www.scopus.com/inward/record.url?scp=85167843535&partnerID=8YFLogxK
U2 - 10.1097/ICU.0000000000000980
DO - 10.1097/ICU.0000000000000980
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 37326216
AN - SCOPUS:85167843535
SN - 1040-8738
VL - 34
SP - 396
EP - 402
JO - Current Opinion in Ophthalmology
JF - Current Opinion in Ophthalmology
IS - 5
ER -